Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION

ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION

November 27, 2024

ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION

ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION

Previous: CRB-701 (SYS6002) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA

Next: BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026)OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat